https://www.selleckchem.com/products/nvp-2.html
Subsequent chromatin immunoprecipitation assays revealed that STAT3 binds to the IL-33 promoter to mediate IL-33 expression. Moreover, SHARPIN-mediated expression of IL-33 was reduced after treatment of HaCaT cells with the JAK/STAT inhibitor ruxolitinib. STAT3 and IL-33 expression levels were higher in AD skin lesion tissues than in normal skin tissues. These findings suggest that SHARPIN modulates inflammation in HaCaT cellsby inhibiting JAK/STAT signalling, supporting the application of SHARPIN as a potential therapeutic target for AD.
Like
Comment
Share
